ArticleBMC gastroenterology2026
Determinants of eligibility for second-line chemotherapy following gemcitabine plus nab-paclitaxel therapy in patients with unresectable pancreatic cancer: a retrospective study.
Tsuyoshi Ueda et al.PubMed ↗Publisher ↗
No numbers read from the abstract.